Skip to main content
S&P 5007,773.95+0.66%DOW51,267.90+0.18%NASDAQ27,477.31+1.05%BTC$86,020.00-0.54%ETH$2,717.65-0.48%GOLD$4,168.00+0.27%OIL$89.22-0.23%
Smart Investors Daily
SID Premium
HUTCHMED (China) Limited American Depositary Shares logo

NASDAQ · HCM

HUTCHMED (China) Limited American Depositary Shares

Healthcare · Drug Manufacturers - Specialty & Generic

$14.20

Up+$0.11 (+0.77%)

Updated Oct 5, 2026, 11:14 PM

SID Score

6.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.39B
P/E ratio
5.13
Dividend yield
0.00%
52-week range
$9.77 – $16.40
Volume
45.74K
Avg. volume
38.74K

Price performance · HCM

HCM price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

HCM closed at $14.20 after 19 trading sessions, up 2.31% for the selected period.

Last close
$14.20
Period change
+2.31%
Period low
$12.82
Period high
$14.63
Daily close
View OHLC price history
HCM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$14.31$14.34$14.10$14.2045.74K
Oct 1, 2026$14.63$14.80$14.57$14.5770.99K
Sep 30, 2026$14.45$14.93$14.45$14.6378.13K
Sep 29, 2026$14.19$14.29$14.03$14.1546.21K
Sep 28, 2026$13.93$14.22$13.93$14.1329.67K
Sep 25, 2026$14.06$14.14$13.915$13.9471.26K
Sep 24, 2026$13.97$14.08$13.81$13.9044.3K
Sep 23, 2026$14.13$14.43$14.10$14.37117.67K
Sep 22, 2026$14.17$14.23$14.01$14.0737.05K
Sep 21, 2026$14.06$14.55$14.06$14.48114.33K
Sep 18, 2026$13.68$13.77$13.57$13.6715.8K
Sep 17, 2026$13.60$13.89$13.60$13.8235.06K
Sep 16, 2026$13.62$13.62$13.38$13.4631.21K
Sep 15, 2026$13.68$13.79$13.585$13.7968.82K
Sep 14, 2026$13.35$13.71$13.35$13.66114.6K
Sep 11, 2026$13.06$13.06$12.79$12.8282.75K
Sep 10, 2026$13.35$13.35$13.09$13.1245.19K
Sep 9, 2026$13.91$13.91$13.51$13.5795.02K
Sep 8, 2026$14.00$14.05$13.70$13.88109.12K

Latest HCM news

The latest Smart Investors Daily articles mentioning HCM.

Stock researchCompany · Overview

HCM research

Overview

Company profile and research snapshot.

Company profile

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$17.50
Implied upside
—
Analysts
27
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

First-in-class KRAS-payload leveraging synchronized EGFR inhibitionHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient received the first dose in China on September 24, 2026. An Antibody-Targeted Therapy Con

Yahoo · Sep 24, 2026

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain. Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination hav

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By